The selection of a drug for antibacterial therapy of infections caused by microorganisms resistant to routinely used antibiotics in clinical practice is a highly complex and often an unachievable task. Unfortunately, the development of pharmacology significantly lags behind the rate of resistance spread among pathogens. There are no new antimicrobial agents, and the same antibiotics that were considered a panacea a decade ago have significantly lost their potential. What to do?

In response, drugs that were unjustly "reserved" due to their "narrow spectrum of activity," "excessive toxicity," or due to being replaced by more modern and "advanced" generations have come to the rescue. One such "old" antibiotic is fosfomycin—a drug with enormous, yet still largely undiscovered, clinical potential.

The article "Fosfomycin: Pharmacological Prerequisites for Effective Antibiotic Therapy" presents the pharmacodynamics and pharmacokinetics that have driven the growing interest and prompted a reassessment by both scientists and clinicians regarding this unique drug.